Novo Nordisk Announces Leadership Overhaul: Maziar Mike Doustdar Appointed CEO and New R&D Unit Established

Reuters
07-29
<a href="https://laohu8.com/S/NVO">Novo Nordisk</a> Announces Leadership Overhaul: Maziar Mike Doustdar Appointed CEO and New R&D Unit Established

Novo Nordisk A/S announced new management changes effective 7 August. Martin Holst Lange will lead a newly merged R&D unit as Chief Scientific Officer, combining Research & Early Development with Development. Emil Kongshøj Larsen will join Executive Management as Executive Vice President of International Operations, succeeding Mike Doustdar. Marcus Schindler, current CSO, will retire, and Mike Doustdar will take on a new leadership role. These changes aim to advance innovation in diabetes and obesity therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001120240-en) on July 29, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10